COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? No.
作者信息
Ley Brett
机构信息
Department of Pulmonary and Critical Care Medicine, Kaiser Permanente San Francisco, and the Department of Medicine, University of California San Francisco.
出版信息
Chest. 2019 Aug;156(2):205-208. doi: 10.1016/j.chest.2019.03.027.
PMID:31395256
Abstract
摘要
Zotero 插件